← Back to Screener

SVRA Report

08-04-2026 | Analyze. Execute. Alpha.

Performance Framework

Earning
Sentiment
Estimate
Short interest
Cdrs
Ta analysis (short term)
Ta analysis (long term)
Insiders action
Institutional conviction
Mf

Key Metrics & Valuation

Market Cap 1.12B$
Next Earning Release 2026-05-12 00:00:00 (NA days)
Correlation to Market 73.2%
Technical Trend Trending up
Current Ratio 11.8
Return on Equity -84.0%
PEG Ratio -1.1
EV/EBITDA -9.1
EV/Revenue 0.0
EV/FCF -11.0
Price to Earning Correlation 36.2%
Total R&D (5yr % of Rev) 60616.6%
Institutional Holding 9405.0%

Earnings & Cash Flow

  • This quarter EPS is 7.1% related to same quarter last year.
  • Annual earning is -10.4% compared to last year.
  • EPS (ttm) in the last 4 quarters is trending down .
  • Annual average earning surprise in the last 5 years is 12.4%.
  • Earnings in the last 5 years, is trending down .
  • 3.0 of the last 4 quarters had positive surprise.

EBITDA

  • This quarter EBITDA is -15.2% related to same quarter last year.
  • Annual EBITDA in the last 5 years, is trending down.

Free Cash Flow (FCF)

  • This quarter FCF is -13.4% related to same quarter last year.

Revenue/Income

Revenue

  • This quarter revenue is 0.0% related to same quarter last year.

Net Income

  • This quarter income is -11.0% related to same quarter last year.
  • Income ratio in the last 4 quarters, is trending down .
  • Net income ratio in the last 5 years, is trending down .

Sentiment

News Sentiment

  • Short term: 51.0% positive, 0.0% negative.
  • Long term: 41.6% positive, 0.0% negative.

Short Interest

  • Short ratio (Days to cover): 17.2
  • Short as % of float: 13.4%
  • Float share amount is trending down.

Future Estimates

Revenue 0.0%
Net Income 13.0%
EPS 12.3%
Price Target Up Side 77.7%

Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Next earning release is on 2026-05-12 00:00:00, in NA days

Technical Analysis

Hourly Momentum

Daily Framework

Weekly Strategic

Interactive Chart

Additional Resources

  • Premium Analysis Locked
  • AI Analyst Reasoning


    Content Locked Premium Analysis Locked (Contact for Access)